 "Glenmark Pharma gets USFDA nod for oral contraceptives")
"Glenmark Generics Inc, USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for the oral contraceptive Levonorgestrel and Ethinyl Estradiol tablets USP, 0.09 mg/0.02 mg, the therapeutic equivalent of Lybrel of Wyeth Phamaceutical Inc (which is no longer being marketed in the US)," Glenmark Pharma said in a filing to the BSE.
Lybrel is indicated for prevention of pregnancy for those who go for oral contraceptives as a method of contraception, it said.
Also Read
The company said the approval marks Glenmark's 11th oral contraceptive authorised for distribution by the USFDA.
It plans to commence shipping of tablets Levonorgestrel and Ethinyl Estradiol, 0.09 mg/0.02mg immediately, stated the filing.
Glenmark's current portfolio consists of 97 products authorised for distribution in the US and 68 Abbreviated New Drug Applications (ANDAs) pending approval with the USFDA.
The company said it continues to identify and explore external development partnerships to supplement and accelerate growth of its existing pipeline and portfolio.
Glenmark Pharma shares were trading 1.42 per cent up at Rs 876.95 apiece during morning session on the BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%